Abstract:
A present invention relates to the synergistic herbal ophthalmic composition, which delays the onset and progression of cataract. The product is suitable for prophylactic treatment of cataract of different degree. The herbs are cleaned coarsely ground, weighed as per formula and extracted using different solvents preferably water, filtered or centrifuged to collect the clear filtrate and formulated in the form of sterile ophthalmic drops, gel, ointment, cream etc for said therapeutic purpose.

Description:
FIELD OF THE INVENTION 
       [0001]    The present invention relates to a synergistic herbal composition for delaying the onset and progression of cataract. 
       BACKGROUND AND PRIOR ART 
       [0002]    Cataract is one of the leading causes of visual disability; often leading to blindness. The situation can only be remedied surgically by extirpation of the cataractous lens. However, even after surgery the disability still remains prevalent in substantial number of individuals. 
         [0003]    Cataract is defined as opacity of the lens and loss of eye lens transparency. Nearly 19 million people are blind due to cataract in the world. The age-adjusted prevalence of cataract in India is three times that of the United States. Apart from aging, various risk factors such as nutritional deficiencies or inadequacies, diabetes, sunlight, environmental factors, smoking and lack of consumption of antioxidants are known to increase the risk of cataract. New medical advances such as surgery and lens replacement have a high degree of efficacy, but are not available or too expensive for most of the world&#39;s population. For this reason, if an intervention is able to delay the onset of cataract by 10 years or so, the number of cataract surgery can be reduced to nearly half. 
         [0004]    The eye lens is a vascular tissue packed with protein that provides the high refractive index necessary for the fine focusing of light onto the retina. Visual impairment in cataract results from opacity or light scattering produced most often by the formation of large protein aggregates in the lens. The process of aggregation involves variety of complex metabolic and physiological mechanisms, which act in combination to change the refractive index. Studies on lens proteins indicate that post translational modifications such as oxidation, glycation, Schiffs base formation; phosphorylation, elevated calcium levels and proteolysis lead to lens opacification. These chemical changes can be regulated to maintain lens homeostasis and transparency. Thus, cataract is believed to be a disease that requires a biochemical and pharmacological, rather than a surgical, solution. 
         [0005]    Although cataract is a multi-factorial disease, it is widely accepted that oxidative free-radical damage is an important factors which initiate development of cataract. Oxidative stress may cause direct modification of the inner lens proteins, such as cross-linking aggregation, and precipitation. Hence oxidative mechanisms through generation of reactive oxygen radicals are believed to play an important role in the progressive decline of vision and formation of cataract. 
         [0006]    In vitro and in vivo studies with experimental animal models as well as the epidemiological studies conducted with selected human populations demonstrated a lower incidence of cataract in the groups consuming higher amount of ascorbic acid and other antioxidants. Reactive oxygen species (ROS) such as hydrogen peroxide, super-oxide radical, singlet oxygen and hydroxyl radical are postulated to contribute to this process. ROS are generated in the eye both enzymatically and photo-chemically. Endogenous defense mechanisms through scavenging of ROS by antioxidant enzymes like super oxide dismutase, glutathione peroxidase, catalase and glutathione-S-transferase, simultaneously protect the lens from oxidative damage. 
         [0007]    Medicinal plant based compositions are being used since long for a variety of diseases. Because of sufficient evidence that oxidative stress play a role in mechanism of cataractogenesis, there has been an increasing interest in the development of suitable antioxidant products of plant origin that could be effective in delaying or preventing the formation of cataract. Flavonoids and related poly-phenols are antioxidants and also potent inhibitors of aldose reductase activity, the key enzyme in diabetic cataract. Further a decreased risk of cataract has been associated with consumption of tea, a major source of flavonoid-quercetin. Quercetin has been shown to inhibit hydrogen peroxide-induced oxidation of the lens proteins. Optimization of dietary intake of protective nutrients has been an effective approach towards reducing the incidence of cataract. 
         [0008]    Curcumin, the active principle of turmeric, has been shown to have both antioxidant and anticataract activity in vitro and in vivo. Green tea also evaluated for anti-cataract potential and it possesses significant antioxidant activity and inhibits oxidative stress-induced experimental cataractogenesis. The aqueous extract of  Ocimum sanctum  protected the cataract in selenite-induced experimental cataractogenesis. A polyherbal preparation, Chyavanprash protects against steroid induced opacities in lens of chick embryo. Many plant extracts are under investigation to exhibit the anti-cataract activity by evaluating them in a various experimental models and estimating the responsible enzymes. However there is no product in the market which is free of side effects and can be effectively used for the treatment of cataract. 
       OBJECT OF THE INVENTION 
       [0009]    The object of the present invention is to develop a synergistic herbal composition and its use as a therapeutic agent for delaying the onset and progression of cataract. 
     
    
     DETAILED DESCRIPTION OF THE INVENTION 
       [0010]    Accordingly present invention provides a synergistic herbal composition for delaying the progression and onset of cataract comprising the extract of  Foeniculam vulgare, Murraya koenigii  and  Triphala  (mixture of equal amount of  Embelica officinalis, Terminalia chebula  and  Terminalia belerica ) optionally along with pharmaceutically acceptable excipient. 
         [0011]    A synergistic herbal composition of the present invention comprises 
         [0000]    
       
         
               
               
               
             
           
               
                   
               
               
                 S. No. 
                 Herbs 
                 % age by weight 
               
               
                   
               
             
             
               
                 1 
                 
                   Foeniculam vulgare 
                 
                 0.10 to 2.0%  
               
               
                 2 
                   Murraya koenigii  extract 
                 0.1 to 2.0% 
               
               
                 3 
                   Triphala  extract 
                 0.1 to 5%   
               
               
                   
               
             
          
         
       
     
         [0012]    A synergistic herbal composition of the present invention preferably comprises 
         [0000]    
       
         
               
               
               
             
           
               
                   
               
               
                 S. No. 
                 Herbs 
                 % age by weight 
               
               
                   
               
             
             
               
                 1 
                 
                   Foeniculam vulgare 
                 
                 0.3% 
               
               
                 2 
                   Murraya koenigii  extract 
                 0.3% 
               
               
                 3 
                   Triphala  extract 
                 0.5% 
               
               
                   
               
             
          
         
       
     
         [0013]    The pharmaceutically acceptable excipient may be selected from the group comprising solubility enhancing agents such as polysorbate, cyclodextrin and their derivative, Cremophore RH 40, Viscosity increasing agents such as Hydroxypropylmethylcellulose and other suitable cellulose derivative, polyvinyl alcohol, povidone, carbopol caragenin, anti oxidants such as citric acid, EDTA and salts thereof, sodium metabisulphite and other approved water soluble anti oxidants, buffering agents such as citrate, borate, phosphate, citro-phosphate and osmolarity adjusting agents such as sodium chloride, mannitol, glycerol, preservatives such as benzalkonium chloride, sorbic acid, methyl paraben, propyl paraben, and salts thereof. 
         [0014]    The synergistic herbal composition of the present invention is preferably in the form of eye drop, ointment, cream or gel suitable for ophthalmic administration. 
         [0015]    The present invention further comprises a process for preparing the said herbal composition. The process of preparing the said herbal composition comprises the following steps:
       (a) Coarsely grinding the individual herb such as herein described and extracting it with solvents having different polarity selected from the group such as water, alcohol, acetone, ethyl acetate, Petroleum ether, chloroform or their mixture in different ratio;   (b) Optionally concentrating the extract obtained in step (a) under vacuum and converting the same either in the form of thick paste having around 20-30% solids or in the form of dry powder;   (c) Formulating pharmaceutically acceptable herbal composition by combining the extracts obtained in step (a) or step (b) in different ratios such as herein described to yield the synergistic herbal composition in the form of eye drop, ointment, cream or gel;   (d) Alternatively the extraction can also be performed using distillation method and distillate can be directly used for formulating synergistic herbal composition such as herein described.       
 
         [0020]    Experimental Procedure: 
         [0021]    The invention is illustrated by the following examples which are not meant to restrict the scope of the invention in any manner 
         [0022]    Although the invention has been described with reference to specific embodiments, this description is not meant to be construed in a limiting sense. Various modifications of the disclosed embodiments, as well as alternate embodiments of the invention, will become apparent to persons skilled in the art upon reference to the description of the invention. It is therefore contemplated that such modifications can be made without departing from the spirit or scope of the present invention as defined. In the examples, “part” and “parts” mean “part by weight” and “parts by weight”, respectively, unless otherwise specified. 
         [0023]    The process for preparing the herbal composition comprises the following steps:
       (i) Extraction of herb: The herbs are cleaned, coarsely ground and extracted with water using 8 times the amount of water by heating it to boil for suitable time. The extract is filtered and concentrated to a thick paste having around 30% of solid content. It is then dried in vacuum drier at a temperature of about 60 C or it can also be spray dried or freeze dried. The dried powder is collected, packed after sieving in double poly bag. Alternatively herbs can be distilled and distillate can be used for further composition development.   (ii) The extracts as per formula are weighed and dissolved in water containing 0.25 HPMC as viscosity increasing agent under stirring. Additionally Cremophore RH 40 may be added to increase the solubility.   (iii) The preparation in centrifuged at about 4000 rpm for 30-60 min to remove the insoluble matter. Alternatively it can be filtered using whatman filter paper.   (iv) To the clear filtrate suitable preservative (in this case, BKC, methyl and propyl paraben sodium and sorbic acid, phenyl ethyl alcohol and mercury containing preservatives are found to be suitable) are dissolved.   (v) Disodium EDTA and sodium metabisulphite as anti oxidants are dissolved in it by stirring   (vi) Finally pH is adjusted with boric acid/borax, citric acid, sodium citrate, potassium and sodium phosphate to 5-7 and volume is made up with water for injection.   (vii) The liquid is then filtered using Millipore filter of 0.22 micron and filled in plastic eye drops vial under laminar flow and labeled.   (viii) The final product is clear, transparent having light brown to yellowish red color having osmolarity of 250-300 mosmol and pH of 5-7.       
 
         [0032]    The different herbal compositions were prepared using following formulae:
       (i)  Foeniculam vulgare  composition (F1) comprises:       
 
         [0000]    
       
         
               
               
               
             
           
               
                   
               
               
                   
                   
                 Quantity for 100 ml 
               
               
                 S. N. 
                 Ingredients 
                 (mg) 
               
               
                   
               
             
             
               
                 1 
                   Foeniculam vulgare  extract 
                 300 
               
               
                 2 
                 Hydroxypropylmethylcellulose 
                 250 
               
               
                 3 
                 Methyl paraben sodium 
                 200 
               
               
                 4 
                 Propyl paraben sodium 
                  20 
               
               
                 5 
                 Disodium EDTA 
                 100 
               
               
                 6 
                 Sodium metabisulphite 
                 100 
               
               
                 7 
                 Boric acid/Borax quantity sufficient to 
                 q.s. 
               
               
                   
                 pH 6.5 
               
               
                 8 
                 Water for injection q.s. to volume 
                 q.s. 
               
               
                   
               
             
          
         
       
       
         
           
             (ii)  Murraya koenigii  composition (F2) comprises: 
           
         
       
     
         [0000]    
       
         
               
               
               
             
           
               
                   
               
               
                   
                   
                 Quantity for 100 ml 
               
               
                 S. N. 
                 Ingredients 
                 (mg) 
               
               
                   
               
             
             
               
                 1 
                   Murraya koenigii  extract 
                 300 
               
               
                 2 
                 Hydroxypropylmethylcellulose 
                 250 
               
               
                 3 
                 Methyl paraben sodium 
                 200 
               
               
                 4 
                 Propyl paraben sodium 
                  20 
               
               
                 5 
                 Disodium EDTA 
                 100 
               
               
                 6 
                 Sodium metabisulphite 
                 100 
               
               
                 7 
                 Boric acid/Borax quantity sufficient to 
                 q.s. 
               
               
                   
                 pH 6.5 
               
               
                 8 
                 Water for injection q.s. to volume 
                 q.s. 
               
               
                   
               
             
          
         
       
       
         
           
             (iii)  Triphala  composition (F3) comprises: 
           
         
       
     
         [0000]    
       
         
               
               
               
             
           
               
                   
               
               
                   
                   
                 Quantity for 100 ml 
               
               
                 S. N. 
                 Ingredients 
                 (mg) 
               
               
                   
               
             
             
               
                 1 
                   Triphala  extract 
                 500 
               
               
                 2 
                 Hydroxypropylmethylcellulose 
                 250 
               
               
                 3 
                 Methyl paraben sodium 
                 200 
               
               
                 4 
                 Propyl paraben sodium 
                  20 
               
               
                 5 
                 Disodium EDTA 
                 100 
               
               
                 6 
                 Sodium metabisulphite 
                 100 
               
               
                 7 
                 Boric acid/Borax quantity sufficient to 
                 q.s. 
               
               
                   
                 pH 6.5 
               
               
                 8 
                 Water for injection q.s. to volume 
                 q.s. 
               
               
                   
               
             
          
         
       
       
         
           
             (iv) Combined  Foeniculam vulgare, Murraya koenigii  and  Triphala  composition (F4) of the present invention comprises: 
           
         
       
     
         [0000]    
       
         
               
               
               
             
               
               
               
             
           
               
                   
               
               
                   
                   
                 Quantity for 100 ml 
               
               
                 S. N. 
                 Ingredients 
                 (mg) 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 1 
                   Foeniculam vulgare  extract 
                 300 
               
               
                 2 
                   Murraya koenigii  extract 
                 300 
               
               
                 3 
                   Triphala  extract 
                 500 
               
               
                 4 
                 Hydroxypropylmethylcellulose 
                 250 
               
               
                 5 
                 Methyl paraben sodium 
                 200 
               
               
                 6 
                 Propyl paraben sodium 
                  20 
               
               
                 7 
                 Disodium EDTA 
                 100 
               
               
                 8 
                 Sodium metabisulphite 
                 100 
               
               
                 9 
                 Boric acid/Borax quantity sufficient to 
                 q.s. 
               
               
                   
                 pH 6.5 
               
               
                 10 
                 Water for injection q.s. to volume 
                 q.s. 
               
               
                   
               
             
          
         
       
     
         [0037]    Throughout this specification, unless the context requires otherwise, the word “comprise” or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. 
         [0038]    Manufacturing Procedure for Composition (F1, F2 and F3):
       1. Hydroxypropylmethylcellulose (HPMC) is dissolved in about 50 ml of water under stirring. Once it is dissolved completely, then main active ingredient as per above formula of Composition (F1, F2, and F3) are added to this and dissolved under stirring.   2. The solution is then centrifuged at 4000 rpm for 30 minutes and clear liquid is collected.   3. Methyl and propyl paraben sodium is dissolved in around 10 ml of water and added to clear filtrate of step 2 under stirring.   4. Item number 5 and 6 are then added and dissolved in main bulk under stirring and pH is checked.   5. pH is then adjusted with dilute boric acid/borax solution and volume is made up.   6. The solution is filtered using 0.22 micron filter aseptically and product is filled in 10 ml three piece plastic vial.       
 
         [0045]    Manufacturing Procedure for Composition (F4):
       1. Hydroxypropylmethylcellulose (HPMC) is dissolved in about 50 ml of water under stirring. Once it is dissolved completely, then main active ingredients (item 1, 2 and 3) as per above formula of Composition (F4) are added to this and dissolved under stirring.   2. The solution is then centrifuged at 4000 rpm for 30 minutes and clear liquid is collected.   3. Methyl and propyl paraben sodium is dissolved in around 10 ml of water and added to clear filtrate of step 2 under stirring.   4. Item number 7 and 8 are then added and dissolved in main bulk under stirring and pH is checked.   5. pH is then adjusted with dilute borax/boric acid solution and volume is made up.   6. The solution is filtered using 0.22 micron filter aseptically and product is filled in 10 ml three piece plastic vial.       
 
         [0052]    The activity of herbal composition was evaluated in vivo, in galactose induced cataract model. Wistar rats (50-70 g) of either sex were used for the study and fed with 30% galactose. 
         [0053]    To evaluate the anti cataract potential of herbal compositions against galactose induced cataract, the rats were divided in to control and treatment groups. A sample was instilled in the form of eye drop (one drop three times a day) starting from one week prior to cataractogenic insult by galactose and was continued till end of the experiment. Instillation of eye drop significantly delayed the onset and the progression of galactose induced cataract as compared to control. The results of these experimental trials are provided below. 
         [0054]    Evaluation of Anti-Cataract Potential: 
         [0000]    
       
         
               
             
               
               
               
               
               
             
           
               
                 TABLE 1 
               
             
             
               
                   
               
               
                 Effect of 0.5%  Triphala  eye drops in galactose induced 
               
               
                 cataractogenesis of rat. 
               
             
          
           
               
                   
                   
                   
                 Control 
                 0.5% Eye 
               
               
                   
                 Days 
                 Stages 
                 (n = 20) 
                 Drops (n = 20) 
               
               
                   
                   
               
               
                   
                 7 th  Day 
                 Normal 
                 — 
                 85% 
               
               
                   
                   
                 Stage-I 
                 100% 
                 15% 
               
               
                   
                   
                 Stage-II 
                 — 
                 — 
               
               
                   
                   
                 Stage-III 
                 — 
                 — 
               
               
                   
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                   
                 Opacity Index 
                 1 
                 0.16** 
               
               
                   
                 14 th  Day 
                 Normal 
                 — 
                 10% 
               
               
                   
                   
                 Stage-I 
                 — 
                 80% 
               
               
                   
                   
                 Stage-II 
                 100% 
                 10% 
               
               
                   
                   
                 Stage-III 
                 — 
                 — 
               
               
                   
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                   
                 Opacity Index 
                 2 
                 1.1** 
               
               
                   
                 21 st  Day 
                 Normal 
                 — 
                 — 
               
               
                   
                   
                 Stage-I 
                 — 
                 80% 
               
               
                   
                   
                 Stage-II 
                 — 
                 — 
               
               
                   
                   
                 Stage-III 
                  85% 
                 10% 
               
               
                   
                   
                 Stage-IV 
                  15% 
                 10% 
               
               
                   
                   
                 Opacity Index 
                 3.15 
                 1.7** 
               
               
                   
                 30 th  Day 
                 Normal 
                 — 
                 — 
               
               
                   
                   
                 Stage-I 
                 — 
                 50% 
               
               
                   
                   
                 Stage-II 
                 — 
                 20% 
               
               
                   
                   
                 Stage-III 
                 — 
                 — 
               
               
                   
                   
                 Stage-IV 
                 100% 
                 30% 
               
               
                   
                   
                 Opacity Index 
                 4 
                 2.3** 
               
               
                   
                   
               
               
                   
                 **P &lt; 0.01 as compared to control. 
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
             
           
               
                 TABLE 2 
               
             
             
               
                   
               
               
                 Effect of 0.3% eye drops of  Foeniculum vulgare  in galactose induced 
               
               
                 cataractogenesis of rat. 
               
             
          
           
               
                   
                   
                   
                 0.3% eye 
               
               
                 Days 
                 Stages 
                 Control (n = 20) 
                 drops (n = 20) 
               
               
                   
               
               
                 7 th  Day 
                 Normal 
                 — 
                  70% (14) 
               
               
                   
                 Stage I 
                 100% (20) 
                 30% (6) 
               
               
                   
                 Stage II 
                 — 
                 — 
               
               
                   
                 Stage III 
                 — 
                 — 
               
               
                   
                 Opacity Index 
                 1 
                 0.3** 
               
               
                 14 th  Day 
                 Normal 
                 — 
                 10% (2) 
               
               
                   
                 Stage I 
                 15% (3) 
                  75% (15) 
               
               
                   
                 Stage II 
                  85% (17) 
                 15% (3) 
               
               
                   
                 Stage III 
                 — 
                 — 
               
               
                   
                 Opacity Index 
                 1.85 
                 1.05** 
               
               
                 21 st  Day 
                 Normal 
                 — 
                 — 
               
               
                   
                 Stage I 
                 — 
                  55% (11) 
               
               
                   
                 Stage II 
                 — 
                 25% (5) 
               
               
                   
                 Stage III 
                 100% (20) 
                 20% (4) 
               
               
                   
                 Stage IV 
                 — 
                 — 
               
               
                   
                 Opacity Index 
                 3 
                 1.65** 
               
               
                 30 th  Day 
                 Normal 
                 — 
                 — 
               
               
                   
                 Stage I 
                 — 
                 25% (5) 
               
               
                   
                 Stage II 
                 — 
                 40% (8) 
               
               
                   
                 Stage III 
                 5% 
                 20% (4) 
               
               
                   
                 Stage IV 
                 95% (9) 
                 15% (3) 
               
               
                   
                 Opacity Index 
                 3.95 
                 2.25** 
               
               
                   
               
               
                 *P &lt; 0.05 as compared to control. 
               
               
                 **P &lt; 0.01 as compared to control. 
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
               
             
           
               
                 TABLE 3 
               
             
             
               
                   
               
               
                 Effect of  Murraya koenigii  (MK) 0.3% eye drops in galactose 
               
               
                 induced cataractogenesis of rat. 
               
             
          
           
               
                   
                 Days 
                 Stages 
                 Control (n = 16) 
                 MK (n = 14) 
               
               
                   
                   
               
               
                   
                 7 th  Day 
                 Normal 
                 — 
                   50% (07) 
               
               
                   
                   
                 Stage-I 
                 100% (16) 
                   50% (07) 
               
               
                   
                   
                 Stage-II 
                 — 
                 — 
               
               
                   
                   
                 Stage-III 
                 — 
                 — 
               
               
                   
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                   
                 Opacity Index 
                 1 
                 0.350** 
               
               
                   
                 14 th  Day 
                 Normal 
                 — 
                  42.8% (06) 
               
               
                   
                   
                 Stage-I 
                 18.75% (3)   
                  57.2% (08) 
               
               
                   
                   
                 Stage-II 
                 81.25% (13)   
                 — 
               
               
                   
                   
                 Stage-III 
                 — 
                 — 
               
               
                   
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                   
                 Opacity Index 
                 1.812 
                 0.571** 
               
               
                   
                 21 st  Day 
                 Normal 
                 — 
                 22.4% (3) 
               
               
                   
                   
                 Stage-I 
                 — 
                 42.2% (6) 
               
               
                   
                   
                 Stage-II 
                 25% (4) 
                 35.4% (5) 
               
               
                   
                   
                 Stage-III 
                  75% (12) 
                 — 
               
               
                   
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                   
                 Opacity Index 
                 2.750 
                 1.142** 
               
               
                   
                 30 th  Day 
                 Normal 
                 — 
                 — 
               
               
                   
                   
                 Stage-I 
                 — 
                 28.0% (4) 
               
               
                   
                   
                 Stage-II 
                 — 
                 7.60% (1) 
               
               
                   
                   
                 Stage-III 
                 6.25% (1)   
                 57.40% (8)  
               
               
                   
                   
                 Stage-IV 
                 93.75% (15)   
                  7.0% (1) 
               
               
                   
                   
                 Opacity Index 
                 3.937 
                 2.142** 
               
               
                   
                   
               
               
                   
                 **P &lt; 0.01 as compared to control. 
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
               
             
           
               
                 TABLE 4 
               
             
             
               
                   
               
               
                 Effect of composition F4 comprising of  Triphala  0.5%, 
               
               
                   Murraya koenigii  0.3% and  Foeniculum vulgare  0.3%) 
               
               
                 eye drops in galactose induced cataractogenesis of rat. 
               
             
          
           
               
                 Days 
                 Stages 
                 Control (n = 16) 
                 Combination (n = 14) 
               
               
                   
               
               
                 7 th  Day 
                 Normal 
                 — 
                  78.5% (11) 
               
               
                   
                 Stage-I 
                 100% (16) 
                  21.5% (03) 
               
               
                   
                 Stage-II 
                 — 
                 — 
               
               
                   
                 Stage-III 
                 — 
                 — 
               
               
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                 Opacity Index 
                 1 
                 0.214** 
               
               
                 14 th  Day 
                 Normal 
                 — 
                 64.20% (9)  
               
               
                   
                 Stage-I 
                 18.75% (3)   
                 35.80% (5)  
               
               
                   
                 Stage-II 
                 81.25% (13)   
                 — 
               
               
                   
                 Stage-III 
                 — 
                 — 
               
               
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                 Opacity Index 
                 1.812 
                 0.357** 
               
               
                 21 st  Day 
                 Normal 
                 — 
                 57.1% (8) 
               
               
                   
                 Stage-I 
                 — 
                 42.9% (6) 
               
               
                   
                 Stage-II 
                 25% (4) 
                 — 
               
               
                   
                 Stage-III 
                  75% (12) 
                 — 
               
               
                   
                 Stage-IV 
                 — 
                 — 
               
               
                   
                 Opacity Index 
                 2.750 
                 0.428** 
               
               
                 30 th  Day 
                 Normal 
                 — 
                 14.4% (2) 
               
               
                   
                 Stage-I 
                 — 
                 50.3% (7) 
               
               
                   
                 Stage-II 
                 — 
                 28.3% (4) 
               
               
                   
                 Stage-III 
                 6.25% (1)   
                  7.0% (1) 
               
               
                   
                 Stage-IV 
                 93.75% (15)   
                 — 
               
               
                   
                 Opacity Index 
                 3.937 
                 1.285** 
               
               
                   
               
               
                 **P &lt; 0.01 as compared to control. 
               
             
          
         
       
     
         [0055]    Comparative Results of Composition of Individual Herbal Ingredients (F1, F2, F3) and Combination Composition (F4) in Terms of Reducing Opacity of Lens. 
         [0000]    
       
         
               
             
               
               
               
               
               
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 5 
               
             
             
               
                   
               
               
                 Opacity index of different composition at different period of time 
               
             
          
           
               
                   
                   
                   
                 
                   F. vulgare 
                 
                   
                   
               
               
                   
                   
                 
                   Triphala 
                 
                 eye drops 
                 
                   M. koeingii 
                 
                 Combination 
               
               
                   
                   
                 eye drops 
                 (0.3%) 
                 eye drops 
                 composition 
               
               
                 Day 
                 Control 
                 (0.5%) (F3) 
                 (F1) 
                 (0.3%) (F2) 
                 (F4) 
               
               
                   
               
             
          
           
               
                 7 
                 1 
                 0.16 
                 0.30 
                 0.35 
                 0.21 
               
               
                 14 
                 2 
                 1.10 
                 1.05 
                 0.57 
                 0.36 
               
               
                 21 
                 3.15 
                 1.70 
                 1.65 
                 1.14 
                 0.43 
               
               
                 30 
                 4 
                 2.30 
                 2.25 
                 2.14 
                 1.28 
               
               
                   
               
             
          
         
       
     
         [0056]    Surprisingly the herbal composition of the present invention comprises  Foeniculam vulgare, Murraya koenigii,  and  Triphala  (F4) along with pharmaceutically acceptable carriers or excipient showed enhanced effects as compared to the individual compositions (F1, F2 and F3). The results clearly indicates that the combination composition has improved opacity of lens and also prevented occurrence of cataract of higher degree in comparison to their individual composition therefore the said herbal composition (F4) is synergistic. 
         [0000]    
       
         
               
             
               
               
               
             
           
               
                 TABLE 6 
               
             
             
               
                   
               
               
                 Effect of Composition (F4) on 30 mM Galactose induced 
               
               
                 osmotic stress in rat lenses: In vitro study. 
               
             
          
           
               
                 Group (n = 6) 
                 GSH μmole/g. of tissue 
                 Polyols μg/mg of tissue 
               
               
                   
               
               
                 Normal 
                 1.49 ± 0.05* 
                  0.05 ± 0.002* 
               
               
                 Control 
                 0.16 
                 1.10 
               
               
                  55 μg/ml 
                 1.47 ± 0.07* 
                 0.24 ± 0.01* 
               
               
                 110 μg/ml 
                 1.10 ± 0.07* 
                 0.84 ± 0.07* 
               
               
                 220 μ/ml 
                 0.91 ± 0.06* 
                     0.97 ± 0.04 ns 
               
               
                   
               
               
                 *P &lt; 0.01, and ns—non significant as compared with control 
               
             
          
         
       
     
         [0000]    
       
         
               
             
               
               
               
             
           
               
                 TABLE 7 
               
             
             
               
                   
               
               
                 Effect of Composition (F4) on 100 μm sodium selenite 
               
               
                 induced oxidative stress in rat lenses: In vitro study. 
               
             
          
           
               
                 Group (n = 6) 
                 GSH μmole/g. of tissue 
                 MDA μmole/g. of tissue 
               
               
                   
               
               
                 Normal 
                 1.22 ± 0.09* 
                 2.80 ± 0.09* 
               
               
                 Control 
                 0.13 
                 26.65 
               
               
                  55 μg/ml 
                 1.11 ± 0.07* 
                 3.29 ± 0.18* 
               
               
                 110 μg/ml 
                 0.87 ± 0.03* 
                 6.26 ± 0.24* 
               
               
                 220 μg/ml 
                 0.50 ± 0.03* 
                 8.44 ± 0.40* 
               
               
                   
               
               
                 *P &lt; 0.01 as compared with control. 
               
             
          
         
       
     
         [0057]    The composition was studied in galactose induced osmotic stress in vitro and various bio chemical parameters were estimated to assess the mechanism of action. The composition was also evaluated in sodium selenite induced cataract in rat pups.